data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Viracta Therapeutics
(NASDAQ:VIRX)
$3.55
0.21[6.29%]
At close: Jun 29
$3.62
0.0700[1.97%]
After Hours: 7:21PM EDT
Day High/Low3.29 - 3.61
52 Week High/Low1.82 - 12.75
Open / Close3.33 / 3.55
Float / Outstanding20.4M / 37.5M
Vol / Avg.194.8K / 321.5K
Mkt Cap133.1M
P/E2.49
50d Avg. Price2.48
Div / Yield-
Payout Ratio-
EPS-0.28
Total Float20.4M

Viracta Therapeutics (NASDAQ:VIRX), Quotes and News Summary

Viracta Therapeutics (NASDAQ: VIRX)

Day High/Low3.29 - 3.61
52 Week High/Low1.82 - 12.75
Open / Close3.33 / 3.55
Float / Outstanding20.4M / 37.5M
Vol / Avg.194.8K / 321.5K
Mkt Cap133.1M
P/E2.49
50d Avg. Price2.48
Div / Yield-
Payout Ratio-
EPS-0.28
Total Float20.4M
Benzinga - Jun 8, 2022, 4:08AM
Benzinga - Jun 2, 2022, 8:31AM
Benzinga - May 10, 2022, 4:39PM
Benzinga - Mar 16, 2022, 8:35AM
Benzinga - Jan 31, 2022, 4:43PM
Benzinga - Jan 31, 2022, 8:32AM
Benzinga - Dec 16, 2021, 8:33AM
Benzinga - Dec 13, 2021, 12:13PM
Benzinga - Dec 13, 2021, 11:36AM
Benzinga - Dec 13, 2021, 11:32AM
Benzinga - Dec 13, 2021, 11:31AM
Benzinga - Nov 29, 2021, 8:02AM
Benzinga - Nov 16, 2021, 10:25AM
Benzinga - Nov 10, 2021, 8:11AM
Benzinga - Nov 5, 2021, 9:03AM
Benzinga - Oct 6, 2021, 8:01AM
Benzinga - Aug 23, 2021, 8:06AM
Benzinga - Aug 18, 2021, 9:38AM
Benzinga - Aug 12, 2021, 8:23AM
Benzinga - Jul 21, 2021, 8:03AM
Sector: Health Care.Industry: Biotechnology
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-11
REV
Q1 2022Est.ActualSurprise
EPS-0.310-0.280 0.0300
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Viracta Therapeutics Questions & Answers

Q
How do I buy Viracta Therapeutics (VIRX) stock?
A

You can purchase shares of Viracta Therapeutics (NASDAQ: VIRX) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Viracta Therapeutics's (VIRX) competitors?
Q
What is the target price for Viracta Therapeutics (VIRX) stock?
A

The latest price target for Viracta Therapeutics (NASDAQ: VIRX) was reported by HC Wainwright & Co. on Monday, May 3, 2021. The analyst firm set a price target for 35.00 expecting VIRX to rise to within 12 months (a possible 885.92% upside). 0 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Viracta Therapeutics (VIRX)?
A

The stock price for Viracta Therapeutics (NASDAQ: VIRX) is $3.55 last updated June 29, 2022, 8:00 PM UTC.

Q
Does Viracta Therapeutics (VIRX) pay a dividend?
A

There are no upcoming dividends for Viracta Therapeutics.

Q
When is Viracta Therapeutics (NASDAQ:VIRX) reporting earnings?
A

Viracta Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.

Q
Is Viracta Therapeutics (VIRX) going to split?
A

There is no upcoming split for Viracta Therapeutics.

Q
What sector and industry does Viracta Therapeutics (VIRX) operate in?
A

Viracta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.